Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD ...

Learn more Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at ...

Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...

The brothers shared an unbreakable bond while living with Duchenne muscular dystrophy, a rare genetic disorder that causes ...

Explore how researchers are using next-generation CRISPR therapies to target the root cause of muscle degeneration.

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

Investigational oral substrate therapy BBP-418 demonstrated significant increases in alpha-dystroglycan glycosylation and improved ambulatory function in the phase 3 FORTIFY interim analysis.

University of Maine researchers have published new findings about how muscles form, why certain muscle diseases develop and ...

Muscular dystrophy (MD) is a group of genetic diseases that cause your muscles to progressively weaken and degenerate. There are several types of MD, each with its own symptoms, but they all involve ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...